Skip to main content

Table 1 Number of patients with observed PK concentration data used in the analysis by study, cancer type and dosing regimen

From: Evaluation of dosing strategy for pembrolizumab for oncology indications

Study Cancer Type 2 mg/kg Q3W 10 mg/kg Q3W 10 mg/kg Q2W 200 mg Q3W
KEYNOTE-001 Melanoma 165 309 176  
KEYNOTE-001 NSCLC 61 288 204  
KEYNOTE-002 Melanoma 207 212   
KEYNOTE-006 Melanoma   270 272  
KEYNOTE-010 NSCLC 327 326   
KEYNOTE-024 NSCLC     152
KEYNOTE-045 Urothelial Cancer     262
KEYNOTE-052 Urothelial Cancer     311
KEYNOTE-055 HNSCC     47
KEYNOTE-164 MSI-H     58
  1. There are patients with missing indication for N = 24 from KEYNOTE-001, 002 and 006
  2. NSCLC Non–Small Cell Lung Cancer, HNSCC Head and Neck Squamous Cell Carcinoma, MSI-H Microsatellite Instability-High Carcinoma